This Plain Language Summary of Publication article (PLSP) from the Journal of Medical Economics estimated healthcare costs when people with non-valvular atrial fibrillation switched from apixaban to rivaroxaban versus staying on apixaban. Using real-world data and cost models for the USA and Germany, researchers analyzed expenses from stroke, systemic embolism, and major bleeding events to understand the economic impact of switching between these blood-thinning medications.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany’ and was published in the Journal of Medical Economics.

Visit Taylor & Francis Online using the link to read the original article.